Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03811847 · ClinicalTrials.gov registry record · Phase 4
A Pilot of Methylphenidate in Mild Cognitive Impairment and Dementia Participants.
A Phase 4 study, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- Phase 4
- Development phase
- 11
- Enrollment target
NCT03811847: Completed Phase 4 study, sponsored by Massachusetts General Hospital.
NCT03811847 is a Phase 4 study that has completed, run by Massachusetts General Hospital. The registered enrollment target is 11 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03811847, a Phase 4 study, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 11 participants
- Enrollment target
Study Summary
Investigators are doing this research study to find out if methylphenidate (MPH) can help people with Mild Cognitive Impairment (MCI) or mild dementia likely due to Alzheimer's Disease (AD) and related disorders (ADRD). The study drug MPH is approved by the U.S. Food and Drug Administration (FDA) to treat Attention Deficit/Hyperactivity Disorder (ADHD), but MPH is not approved by the FDA to treat Mild Cognitive Impairment or mild dementia related to Alzheimer's Disease. However, other studies have been done in which MPH has been given to people with neurodegenerative dementias and results have shown some improvement in these people's mood and cognition. Investigators would like to see if MPH will help mood and cognition. This study will take place completely virtually (with the option to come in for the first visit to meet the study team). All study visits will occur over a secure videoconferencing platform. All study materials will be shipped directly to the home of each participant.
Interventions
- OTHER Placebo
- DRUG Methylphenidate Extended Release Oral Capsule
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2019-11-01 |
| Est. Completion | 2021-08-30 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03811847
The ClinicalTrials.gov registry entry for NCT03811847 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03811847 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03811847 about?
NCT03811847 is a clinical study titled "A Pilot of Methylphenidate in Mild Cognitive Impairment and Dementia Participants.". Investigators are doing this research study to find out if methylphenidate (MPH) can help people with Mild Cognitive Impairment (MCI) or mild dementia likely due to Alzheimer's Disease (AD) and related disorders (ADRD). The study drug MPH is approved by the U.S. Food and Drug Administration (FDA) t...
What is the current status of trial NCT03811847?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 11 participants. The study started on 2019-11-01. Estimated completion is 2021-08-30.
What interventions are being tested in trial NCT03811847?
The interventions under investigation include: Placebo (OTHER), Methylphenidate Extended Release Oral Capsule (DRUG).
Who is sponsoring clinical trial NCT03811847?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.